SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Drug Development
TG Therapeutics Announces Preliminary Results From Ongoing Phase II Study Of TG-1101 (Ublituximab) In Patients With Multiple Sclerosis At The American Academy of Neurology
April 28, 2017
 · 
6 min read
Drug Development
TG Therapeutics Rockets After Leukemia Drug Clears Hurdle in Late-Stage Study
March 6, 2017
 · 
10 min read
Bay Area's Depomed Craters as New CEO, Directors are Named in Deal with Activist Investor
Drug Development
TG Therapeutics, Inc. Stock Plunges as Company Modifies Phase III Cancer Trial Protocols
October 14, 2016
 · 
2 min read
Drug Development
TG Therapeutics, Inc. Launches First Clinical Trial In Multiple Sclerosis (MS) For TG-1101 (Ublituximab)
May 3, 2016
 · 
6 min read
Drug Development
TG Therapeutics, Inc. Announces Data Presentations For TGR-1202 And TG-1101 In Combination With Ibrutinib At The 57th American Society of Hematology Annual Meeting
December 7, 2015
 · 
8 min read
Drug Development
TG Therapeutics, Inc. Announces Data Presentations At The 57th American Society of Hematology Annual Meeting From Ongoing Clinical Studies In Patients With Non-Hodgkins Lymphoma (NHL) And Chronic Lymphocytic Leukemia (CLL)
December 7, 2015
 · 
8 min read
TG Therapeutics, Inc. Recaps Schedule Of Data Presentations At The 57th American Society of Hematology Annual Meeting
December 4, 2015
 · 
3 min read
Business
TG Therapeutics, Inc. Announces Third Quarter 2015 Financial Results And Business Update
November 9, 2015
 · 
1 min read
Business
TG Therapeutics, Inc. To Host Conference Call On Third Quarter 2015 Financial Results And Business Update
November 4, 2015
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. To Present At The Ladenburg Thalmann 2015 Healthcare Conference
September 25, 2015
 · 
1 min read
Drug Development
TG Therapeutics, Inc. Announces Special Protocol Assessment (SPA) Agreement With The FDA For The First Phase 3 Clinical Trial Of Its Proprietary Combination Regimen Of TG-1101 (ublituximab) In Combination With TGR-1202 For Patients With Chronic Lymphocyti
September 17, 2015
 · 
7 min read
Pharm Country
TG Therapeutics, Inc. To Participate In Upcoming Investment Conferences In September
September 9, 2015
 · 
1 min read
Drug Development
TG Therapeutics, Inc. Launches Phase I/II “Triple-Therapy” Study With TGR-1202 + TG-1101 + The PD-1 Checkpoint Inhibitor Pembrolizumab In Patients With Advanced Chronic Lymphocytic Leukemia (CLL) At The University of Pennsylvania’s Abramson Cancer Center
September 9, 2015
 · 
5 min read
Business
TG Therapeutics, Inc. Announces Second Quarter 2015 Financial Results And Business Update
August 10, 2015
 · 
10 min read
Business
TG Therapeutics, Inc. To Host Conference Call On Second Quarter 2015 Financial Results And Business Update
August 5, 2015
 · 
1 min read
Drug Development
TG Therapeutics, Inc. Release: Updated Results From Phase II Clinical Trial Of TG-1101 (Ublituximab) In Combination With Ibrutinib Confirms Robust Clinical Activity With A Favorable Safety Profile In Patients With Previously Treated, High-Risk Chronic Lym
June 18, 2015
 · 
8 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS